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Molecular mechanisms of oncostatin M (OSM)-stimulated cartilage extracellular matrix catabolism and signaling pathways were investigated
in human arthritic chondrocytes. OSM, alone or with Interleukin-1 (IL-1β), increased glycosaminoglycan release and induced ADAMTS-4 and
MMP-13 protein expression in human cartilage explants. OSM dose- and time-dependently increased ADAMTS-4 mRNA and MMP-13 protein
expression in human femoral head chondrocytes. Extracellular signal-regulated kinases (ERK1/2)-MAPK pathway inhibitor, U0126, down-
regulated ADAMTS-4 and MMP-13 induction by OSM. Janus kinase 2 (JAK2) inhibitor, AG490, suppressed OSM-induced ADAMTS-4 mRNA
expression but did not affect MMP-13 levels while JAK3 pharmacological inhibitor and siRNA transfection suppressed both. Parthenolide, a
signal transducer and activator of transcription (STAT1 and STAT3) phosphorylation inhibitor, reduced OSM-induced ADAMTS-4 and MMP-13
gene expression and prevented STAT1/3 DNA binding activity. Additionally, OSM-enhanced ADAMTS-4 mRNA and MMP-13 expression was
down-regulated by phosphatidylinositol 3-kinase (PI3K) and Akt/PKB inhibitors, LY294002 and NL-71-101. Furthermore, JAK3 inhibition time-
dependently down-regulated Akt but not ERK1/2 phosphorylation suggesting that Akt is a downstream target of JAK3. These results suggest that
OSM-stimulated ADAMTS-4 and MMP-13 expression is mediated by ERK1/2, JAK3/STAT1/3 and PI3K/Akt and by cross talk between these
pathways. The inhibitors of these cascades could block OSM-evoked degeneration of cartilage by ADAMTS-4 and MMP-13.
© 2006 Elsevier B.V. All rights reserved.Keywords: Arthritis; Human chondrocytes; Matrix metalloproteinase; ADAMTS; Oncostatin M; Cell signaling1. Introduction
The integrity of cartilage depends upon balance between
matrix-degrading matrix metalloproteinases (MMPs) and
tissue inhibitors of metalloproteinases (TIMPs) that is
controlled by the levels of proinflammatory and anti-
inflammatory cytokines. These homeostatic balances are
altered in arthritic joints due to excessive proinflammatory
cytokines derived from endogenous and exogenous cells in
synovium and cartilage [1,2]. Oncostatin M (OSM), a major
cytokine produced by macrophages, neutrophils [3] and T
cells, has both pro- and anti-inflammatory activities in vivo. Its
levels are elevated in the patients with rheumatoid arthritis
(RA) [4]. OSM by itself contributes to cartilage and bone loss⁎ Corresponding author. Tel.: +1 514 890 8000x25690; fax: +1 514 412 7612.
E-mail address: Muhammad.Zafarullah@umontreal.ca (M. Zafarullah).
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doi:10.1016/j.bbamcr.2006.11.018in RA [5]. Blocking antibodies to OSM in mouse models of
RA ameliorate arthritis [6]. Although not elevated in
osteoarthritic (OA) synovial fluid [4], specific interaction of
OSM with interstitial collagens [7] may contribute to its
availability and local activities.
Loss of principal cartilage proteoglycan, aggrecan (which
gives compressive stiffness) in arthritis occurs by multiple
proteases. By measuring the activity with an aggrecan
neoepitope antibody, aggrecanases or ADAMTS (A Disin-
tegrin And Metalloproteinase with thrombospondin motifs)
were shown to cleave efficiently at multiple sites of the
aggrecan core protein including between Glu373–Ala374 [8].
ADAMTS-4 also cleaves at MMP site, Asn341–Phe342 [9].
The c-terminal thrombospondin motif (TSP-1) of aggrecanase-
1 binds with glycosaminoglycans of aggrecan and is critical
for substrate recognition and cleavage [10]. ADAMTS-4-
generated products are found in the cartilage and synovial fluid
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catabolism [11]. OSM and IL-1 combination induces
ADAMTS-4 RNA in human chondrocytes [12]. Both
ADAMTS-4 and-5 are expressed in human arthritic synovium,
though only former is inducible [13] and ADAMTS-4 cleaves
aggrecan 2 times faster than ADAMTS-5 [14]. However,
ADAMTS-5 is important for cartilage degradation in the
mouse models of OA and RA [15,16]. The role of this enzyme
in human arthritis remains to be elucidated. Thus, proteases
from both synovial linings and chondrocytes can cause
cartilage degradation. Aggrecanases are key targets for
developing cartilage protective therapies, however, nothing is
known about the proinflammatory/catabolic cytokine signaling
and regulatory mechanisms controlling their expression in
human femoral chondrocytes.
MMP-13 (collagenase-3) is another major enzyme that
cleaves and denatures type II collagen 5–10 times more
effectively than collagenase-1 in OA cartilage [17,18]. It also
cleaves aggrecan at a different site [19]. Its expression is
increased in OA cartilage [20]. Direct injection into knee or
cartilage-specific overexpression of active human MMP-13 in
joints led to tissue damage in transgenic mice, suggesting major
implication of this enzyme in arthritis [21]. OSM alone and with
other proinflammatory cytokines induces MMP-13 in articular
chondrocytes [22]. Cytokine-stimulated proteolytic actions of
aggrecanases followed by MMP-13 result in degradation of
matrix components in human arthritic tissues and their
inhibition is a valid therapeutic approach.
OSM stimulates ERK1/2, JNK1/2, p38 kinase and JAK/
STAT activation in chondrocytes [22]. The PI3 kinase and its
downstream kinases such as Akt/PKB kinase play a funda-
mental role in many biological functions such as cell growth,
differentiation, survival, cytoskeletal organization, cell motility
and inflammation [23]. The current study was aimed to identify
the signal transduction pathways implicated in ADAMTS-4
induction by OSM compared to those of MMP-13. We demon-
strate that OSM-induced ADAMTS-4 and MMP-13 expression
is mediated by ERK, JAK/STAT and PI3K/Akt pathways in
primary human chondrocytes from arthritic patients.
2. Experimental procedures
2.1. Materials
Recombinant human OSM and IL-1β were from R&D Systems (Minnea-
polis, MN). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine
serum were purchased from Invitrogen (Burlington, ON). Human chondrosar-
coma cell line, SW1353 was obtained from American Type Culture Collection
(Manassas, VA). The phospho-specific p44/42 ERK (T202/Y204) E10
monoclonal and Akt/PKB antibodies were purchased from Cell Signaling
(Pickering, ON). ADAMTS-4 (ab-16297) antibody was from Abcam (Cam-
bridge, MA). Double-stranded STAT3 consensus oligonucleotides were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). U126, LY-
294002, NL-71-101, JAK3 inhibitor I, and AG490 were from Calbiochem (La
Jolla, CA). Nitrocellulose membranes were from Bio-Rad (Mississauga, ON).
Enhanced chemiluminescence (ECL) reagent, leupeptin, pepstatin, aprotinin and
fungal (Streptomyces griseus) pronase were from Roche Diagnostics (Laval,
QC). MMP-13 (M4052) antibody (that detects both pro- and active forms of
enzyme), bacterial (Clostridium histolyticum) collagenase type 1A and all other
reagents were from Sigma (St. Louis, MO). JAK3 SMART pool siRNAs werepurchased from Upstate (Lake Placid, NY). TransAM™ AP-1 assay kit was
from ActiveMotif (Carlsbad, CA).
2.2. Methods
2.2.1. Human cartilage explants, culture of primary chondrocytes and SW1353
chondrocytic cells
The use of human tissues was approved by the institutional ethics
committee. Human articular cartilage was obtained from the femoral heads of
patients undergoing hip replacement surgery due to late-stage OA (female
n=15 and age between 46 and 97 years, male n=12 and age between 47
and 89 years). Cartilage fragments (40–45 mg) were excised from the
superficial and medial layers and cultured in 2 ml of DMEM supplemented
with 10% fetal calf serum (FCS), penicillin (100 U/ml) and streptomycin
(100 μg/ml) for 24 h prior to stimulating with different cytokines. For cell
culture, immediately after harvesting the cartilage, the pieces were digested
first with pronase for 60 min and then with collagenase for 9 h in DMEM. The
chondrocytes were washed with phosphate buffered saline (PBS) and grown in
DMEM supplemented with 10% FCS as high-density primary monolayer
cultures until confluent growth. Cells were distributed in 6-well plates, grown
to confluence, washed with PBS and kept in serum-free DMEM for 48 h.
Human chondrosarcoma cell line, SW1353, was treated as described below for
primary chondrocytes.
2.2.2. Glycosaminoglycan measurement by DMMB assay
Explants of human cartilage (40–45 mg) were stimulated with OSM (50 ng/
ml) and/or IL-1β for 3 days in DMEM. Conditioned media were used to
evaluate MMP-13 expression by Western blot and glycosaminoglycan (GAG)
content by the dimethylmethylene blue (DMMB) assay based on the procedure
of Farndal et al. [24].
2.2.3. RNA extraction and RT-PCR
Total RNA was extracted as previously described and aliquots of 3–5 μg
analyzed by electrophoretic fractionation in 1.2% formaldehyde-agarose gels
[22]. The integrity and quantity of applied RNA were verified by ethidium
bromide staining of the gels and photography of the 28S and 18S ribosomal
RNA bands. For RT-PCR, 2 mg of RNA was heated for 5 min at 65 °C and
reverse transcribed in the mixture consisting of oligo d (T) 12–18mer, dNTPs,
RNase inhibitor (Pharmacia), acetylated BSA (Promega) with Moloney murine
leukemia-virus reverse transcriptase (MMLV-RT) (Invitrogen) according to the
protocols of Clontech Laboratories Inc. (Paolo Alto, CA). Conditions of RT-
PCR were same as described before for aggrecanase-1-specific primers [25].
The amplification profile was one cycle at 94 °C for 1 min, 35 cycles of 94 °C
for one min, hybridization at 60 °C for 2 min and extension at 72 °C for 3 min.,
followed by one extension cycle of 7 min at 72 °C. The PCR was performed in
a DNA cycler (Techne, Princeton, NJ) in a 50-ml reaction with 1.25 mM
dNTPs, Taq DNA polymerase (Pharmacia) and respective primers. Aliquots of
10 ml from the 50 ml PCR reaction were analyzed on 1.4% agarose gels to
detect ADAMTS-4 and glyceraldehyde phosphate dehydrogenase (GAPDH)
cDNA amplification products of 692 and 226 bp respectively. Negative
controls included either all the RT-PCR reagents except cDNA or additionally,
RT was omitted before PCR. None of these controls gave any bands. Semi-
quantitative estimates were obtained with NIH ImageJ 1.32j (National Institute
of Health, USA) software by dividing ADAMTS-4 band intensities with those
of GAPDH.
2.2.4. Western blot analysis
For measuring MMP-13 expression levels, chondrocytes were preincubated
with different inhibitors (U0126 or parthenolide 5, 10 μM), JAK3 inhibitor (10,
30 μg/ml), LY-294002 and NL-71-101 (10, 20 μM) for 30 min. Cells were then
stimulated with OSM (50 ng/ml) for 24 h. Total secreted proteins from 2 ml of
conditioned medium of chondrocytes were concentrated by precipitation with
trichloroacetic acid (TCA) and quantified by the Bio-Rad protein assay system.
Proteins (5 μg) were separated by 10% SDS-PAGE. Blots were blocked in TBS-
T containing 5% dry milk for 20 min at 37 °C. Thereafter, blots were probed
with a polyclonal antibody against MMP-13 (1/1000 dilution) in blocking
buffer at 4 °C overnight. Subsequently, membranes were washed in TBS-T
buffer five times for 5 min. Detection was carried out using anti-rabbit
Fig. 2. OSM-stimulated ADAMTS-4 andMMP-13 expression in human femoral
chondrocytes. (A) Chondrocytes in serum-deficient media were stimulated with
increasing concentrations of OSM. Representative RT-PCR of ADAMTS-4 and
GAPDH mRNA and Western blots of MMP-13 are shown. (B) Representative
time course of ADAMTS-4 and MMP-13 mRNA expression induced by OSM.
(C) Representative RT-PCR of ADAMTS-4 and GAPDH mRNA and Western
blots of MMP-13 from the conditioned media of chondrocytes stimulated with
OSM (50 ng/ml), IL-1β (10 ng/ml) or both.
Fig. 1. Effect of OSM and IL-1β on cartilage catabolism. Cartilage from human
femoral heads was cultured for 3 days in the absence or presence of OSM (50 ng/
ml), IL-1β (10 ng/ml) or both in serum-free medium. (A) Effect of OSM and IL-
1β glycosaminoglycans (GAG) release in the media. Data represent the means±
SEM of 3 different experiments. (B) RepresentativeWestern blot of ADAMTS-4
expression (active form) in untreated (control) and OSM-stimulated human
cartilage. (C) Representative Western blots of MMP-13 expression from the
conditioned media of 2 different patients after 3 days stimulation with different
cytokines. The bands correspond to the molecular mass of latent proenzyme
(upper band) and active form (lower band).
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Blots were developed by Enhanced Chemiluminescence (ECL). Band
intensities were quantified by NIH ImageJ 1.32j (National Institute of Health,
USA) software.
For Western blot analysis of ADAMTS-4, explants were stimulated with
OSM and/or IL-1β for 3 days, frozen in liquid nitrogen immediately and stored at
−80 °C. Frozen explants were pulverized under liquid nitrogen and proteins in
the resulting powder were extracted with Tris buffer (50 mM Tris, pH 7.0,
100mMNaCl and 1 μg/ml aprotinin, 0.7 μg/ml pepstatin, 1 μg/ml leupeptin, and
1 mM phenylmethylsulfonyl fluoride) for 20 h. Extracts were lyophilised for 4 h
to concentrate the proteins. Total protein (50 μg) was separated by electrophor-
esis on a 10% SDS-PAGE and transferred onto a polyvinylidene fluoride
membrane. Blots were treated as described above. Membranes were incubated
with specific antibodies to ADAMTS-4 (abcam-ab162970) at dilutions of 1:500
(overnight at 4 °C) and second antibody (1/5000, 1 h at room temperature).
For Western blot analysis of phosphorylated ERK1/2 and Akt/PKB, human
chondrocytes were pretreated for each time point with JAK3 inhibitor (30 μg/ml)
and then stimulated with OSM (0–30 min). These cells were washed three times
with cold PBS and lysed in a buffer which contained 20 mM HEPES (pH 7.5),
20 mM NaCl, 1 mM orthovanadate, 1 mM sodium fluoride, 5 mM EDTA, 1%
Nonidet P-40, 1 μg/ml aprotinin, 0.7 μg/ml pepstatin, 1 μg/ml leupeptin, and
1 mM phenylmethylsulfonyl fluoride. Cell lysates were centrifuged at
14,000 rpm for 20 min. Proteins (15 μg) were separated by 10% SDS-PAGE.
Blots were treated as described above. Polyclonal phospho-specific antibodies
against ERK1/2 or Akt/PKB (1/1,000 dilution) in blocking buffer at 4 °C
overnight were used to detect the active forms of these kinases. The same p-ERK1/2 and p-Akt/PKB nitrocellulose membranes were used to probe the total
forms of ERK1/2 and Akt/PKB without stripping.
2.2.5. Electrophoretic mobility shift assay (EMSA)
SW1353 cells in 6-well plates were grown to 100% confluence, washed with
PBS and kept in serum-free DMEM for 48 h. Parthenolide was added at a
concentration of 5–10 μM respectively 30 min before treatment with human
OSM (50 ng/ml). Nuclear extracts were prepared as described [26] with some
modifications. After 40 min treatments, the cells were washed twice with cold
PBS (pH 7.4) and detached by scraping, recovered by centrifugation at
10,000 rpm for 5 min at 4 °C. The cells were lysed in ice cold buffer A [10 mM
HEPES (pH 7.9), 1.5 mMMgCl2, 10 mM KCl, 0.5 mM DTT, 1 mM PMSF, 1%
NP 40, 1 mM NaF and 10 mg/ml protease inhibitors leupeptin A and pepstatin]
and mixed by pipetting. After incubation on ice for 10 min, the contents were
centrifuged at 4000 rpm for 2 min. The nuclear pellets were suspended in 60 ml
of ice cold buffer B [20 mM HEPES (pH 7.9), 420 mM NaCl, 25% glycerol,
1.5 mM MgCl2, 0.2 mM EDTA, 1 mM NaF, 0.5 mM DTT, 0.5 mM PMSF and
10 mg/ml protease inhibitors, leupeptin and pepstatin A] and kept on ice for
30 min with gentle shaking and then centrifuged at 12,000 rpm for 15 min at 4
°C. The nuclear protein supernatants were recovered and protein concentrations
were determined by Bio-Rad protein assay. The double-stranded oligonucleotide
containing the STAT3 consensus (Santa Cruz Biotechnology) sequence was end
labeled with [γ-p32] ATP by T4 polynucleotide kinase. Nuclear extracts (5 mg)
were incubated with 20,000 CPM of labeled probe for 20 min at room
temperature in binding buffer [10 mM Tris–HCl (pH 7.5), 4% glycerol, 1 mM
MgCl2, 0.5 mM EDTA, 0.5 mMDTT, 50 mMNaCl and 50 mg/ml poly (dI. dC)]
and DNA protein complexes were resolved on a 5% non-denaturing
polyacrylamide gel at room temperature. The TransAM AP-1 family kit was
used to measure c-Fos and c-Jun activation and nuclear binding. The metho-
dology was based on the manufacturer's instructions.
2.2.6. Transfection of siRNA by Calcium phosphate method
Suspended SW1353 chondrosarcoma cells (5×105 cells) were incubated
with 100 nM of JAK3 SMART pools siRNA by Calcium phosphate
precipitation method for 20 min and seeded in 10% serum-containing media
Fig. 3. Inhibition of OSM-induced ADAMTS-4 and MMP-13 expression by the MEK-1/2 inhibitor, U0126. Quiescent human chondrocytes were pre-treated with
an inhibitor of this pathway, U0126 (5–10 μM), and then stimulated with OSM for 24 h. Representative RT-PCR of ADAMTS-4 and GAPDH mRNA (A) and
Western blot of MMP-13 protein (C) extracted from conditioned medium. (B and D) Quantitative data represent the means±SE of at least 3 different
experiments. *P<0.05.
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medium was added for 24 h at 37 °C in 5% CO2–95% air. Thereafter, cells
were incubated for 24 h in serum-free media and then stimulated with OSM for
24 h.
2.2.7. Statistical analysis
Results are reported as means±SE and were compared by ANOVA, followed
by a post hoc Newman–Keuls multiple comparison test. P<0.05 was considered
significant.3. Results
3.1. Oncostatin M and Interleukin 1 promote aggrecan
degradation and ADAMTS-4 and MMP-13 expression in
human cartilage explants
To evaluate the impact of OSM and IL-1β on human
chondrocytes in their native extracellular matrix, cartilage
explants were stimulated with OSM (50 ng/ml) and/or IL-1β.
OSM alone or in combination with IL-1β increasedglycosaminoglycan (GAG) release in the media after 3 days
(∼3 fold) (Fig. 1A). The two separate treatments increased
the GAG release at the same magnitude and combined
stimulation of OSM and IL-1β did not show any synergistic
effect.
Fig. 1B shows the active form of ADAMTS-4 expression
induced by OSM in human cartilage after 3 days of
stimulation. This is likely to be the major active ADAMTS-
4 form since IL-1α enhances the production of this form in
cartilage [27]. The results from two different patients show
the levels of MMP-13 protein expression induced by OSM,
IL-1β and combined OSM and IL-1β treatments (Fig. 1C).
OSM or IL-1β alone induced MMP-13 expression. The
combination of these cytokines had an additive effect on
MMP-13 proenzyme and active form expression. The basal
levels of MMP-13 expression were found to be elevated in
some patients (as in patient 1). Despite differences in the
basal MMP-13 expression, the profiles of OSM and IL-1β
responses were the same.
Fig. 4. Impact of JAK3 and JAK2 inhibitors on OSM-induced ADAMTS-4 and MMP-13 gene expression in chondrocytes. Quiescent human chondrocytes were
pretreated with JAK3 inhibitor (10–30 μg/ml) (A) or JAK2 inhibitor (AG 490, 10–20 μM) (B) for 30 min, followed by additional treatment with 50 ng/ml OSM for
24 h. (A and B) Representative agarose gels depicting ADAMTS-4 and GAPDH mRNA expression (upper and middle panels) and Western blots of MMP-13 protein
expression (lower panels). (C, D and E) Quantified data represent the means±SE of at least 3 different experiments for JAK3- and 2 different experiments for JAK2
inhibitor-treated chondrocytes. *P<0.05 and **P<0.01.
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Fig. 5. Effects of JAK3 siRNA on OSM-induced ADAMTS-4 mRNA and MMP-13 in SW1353 chondrosarcoma cells. SW1353 cells were transiently transfected
with JAK3 SMARTpool® siRNA or non-specific control SMARTpool siRNA for 24 h and stimulated with OSM for 24 h. (A) Representative agarose gel of RT-
PCR analysis and Western blots of MMP-13 protein expression shows the attenuated OSM-induced ADAMTS-4 mRNA (upper panel) without affecting GAPDH
mRNA (middle panel) and MMP-13 protein expression (lower panel). Non-specific control SMARTpool siRNA did not affect OSM-induced ADAMTS-4 mRNA
or MMP-13 expression. (B) Representative Western blots of JAK3 analyzed 24 h after transfection. JAK3 protein expression was reduced (∼70%) after siRNA
transfection compared with non-transfected control cells, while transfection with a non-targeted siRNA had no effect on JAK3 protein expression levels. (C) Cells
were transfected with 100 nM of Fluorescein-conjugated siRNA and observed 16 h post-transfection in order to monitor the transfection efficiency. The
transfection efficiency is almost 98% by counting the number of positives cells in 4 different fields. Phase contrast (upper) and fluorescent microscope (lower)
views are shown.
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expression in human chondrocytes
The responsiveness of human chondrocytes to OSM was
evaluated by stimulating the cells with increasing doses of
OSM (1–100 ng/ml). OSM dose-dependently increased
ADAMTS-4 mRNA expression and MMP-13 proenzyme or
its active form expression in human chondrocytes (Fig. 2A).
The minimal dose of 10 ng/ml of OSM was sufficient to
induce the expression of both enzymes. However, an effective
dose of 50 ng/ml was used in subsequent experiments. OSM
caused a time-dependent increase of ADAMTS-4 and MMP-
13 mRNA by 16 h that lasted until 32 h (Fig. 2B). Further,
OSM and IL-1β (10 ng/ml) had an additive effect on
ADAMTS-4 mRNA and MMP-13 expression (Fig. 2C).
GAPDH control mRNA expression was unaffected by these
treatments. We measured ADAMTS-4 mRNA because the
amount of protein of this enzyme was quite low or evenFig. 6. Inhibition of OSM-induced ADAMTS-4 and MMP-13 expression by parthen
(A) Representative agarose gels showing RT-PCR of ADAMTS-4 and GAPDH mR
expression (lower panel). (B) Data represent the means±SE of at least 3 different ex
30 min with parthenolide followed by treatment with OSM for 40 min. Nuclear pro
(c-fos/c-jun) binding activity (D). A representative of 3 experiments is shown.undetectable after 24-h stimulation of chondrocytes with OSM
grown in 6-wells plates.3.3. ERK pathway inhibition suppresses OSM-induced
ADAMTS-4 and MMP-13 expression
To investigate the role of ERK-MAPK pathway in OSM
induction of ADAMTS-4 and MMP-13 expression, primary
human femoral head OA chondrocytes were pre-treated with an
inhibitor of this pathway, U0126, which inhibits the inactive and
active MEK-1/2 [28], and then stimulated with OSM.
ADAMTS-4 mRNA (Fig. 3A and B) and the active form of
MMP-13 protein (Fig. 3C and D) expression were potently
induced by OSM over the basal levels and U0126 dose-
dependently reduced their induction. GAPDH control mRNA
expression was unaffected by these treatments. Since the basal
level of the MMP-13 proenzyme varies among theolide in chondrocytes. Human chondrocytes were treated as in previous figures.
NA expression (upper and middle panels) and Western blot of MMP-13 protein
periments. *P<0.05. (C) SW1353 chondrosarcoma cells were pre-incubated for
tein extracts were then analyzed by EMSA for the STAT3 DNA (C) and AP-1
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Fig. 7. Mediation of OSM-stimulated ADAMTS-4 mRNA expression by Akt/PKB pathway. Quiescent human chondrocytes were pretreated with the indicated
concentrations of PI3/K (LY294002) or Akt/PKB inhibitor (NL-71-101) and stimulated with OSM. Representative RT-PCR analysis and agarose gel shows the
attenuated OSM-induced ADAMTS-4 mRNA (upper panels) expression without affecting GAPDH mRNA expression (middle panels) after 24 h stimulation. Lower
panels depict quantitative data representing the means±SE of at least 3 different experiments *P<0.05. **P<0.01.
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MMP-13 is being depicted in this and subsequent figures.3.4. JAK3 inhibitor and siRNA down-regulate OSM-stimulated
ADAMTS-4 and MMP-13 expression
Since JAK/STAT pathway mediates OSM induction of
MMP-13 [22], we investigated the role of this cascade in OSM-
stimulated ADAMTS-4 gene expression. MMP-13 was also
analyzed for comparison. Pretreatment with JAK3-specific
inhibitor at different concentrations (10–30 μg/ml) or transfec-
tion with JAK3 SMART pool siRNA completely suppressed
ADAMTS-4 mRNA induction without affecting the GAPDH
RNA levels. (Figs. 4A and 5A). Non-targeted negative control
siRNA did not affect the expression of JAK3, ADAMTS-4 and
MMP-13 expression (Fig. 5). Further, MMP-13 protein
induction by OSM was also decreased by JAK3 inhibitor in a
dose-dependent fashion (Fig. 4A and E). Knockdown of JAK3
by SMART pool siRNA partially decreased the OSM-induced
MMP-13 protein expression (Fig. 5A). This incomplete
inhibition could be due to partial knockdown of JAK3 byspecific siRNA (∼70%) (Fig. 5B). SW1353 chondrocytic cell
line was used in the experiments of Fig. 5 due to low
transfection efficiency of human primary chondrocytes. As
depicted in Fig. 5C, very high-efficiency transfection can be
achieved by modified Calcium phosphate method using
trypsinized and suspended cells. JAK2-specific inhibitor
(AG490) dose-dependently attenuated ADAMTS-4-induction
by OSM in human chondrocytes but did not inhibit OSM-
induced MMP-13 expression (Fig. 4B and D).3.5. Parthenolide diminishes OSM-induced ADAMTS-4 and
MMP-13 expression and STAT-3-DNA binding
Parthenolide is an inhibitor of STAT1 and STAT3 phosphor-
ylation, which prevents their dimerization and localization to
nucleus [29]. Pretreatment with parthenolide (10 μM) partially
(ADAMTS-4) or completely (MMP-13) inhibited OSM induc-
tion of these genes (Fig. 6A and B). Analysis of nuclear extracts
from the OSM-treated human SW1353 chondrocytic cells by
EMSA revealed that OSM induced STAT3 DNA binding
activity and parthenolide inhibited such binding (Fig. 6C).
Fig. 8. Suppression of OSM-inducedMMP-13 expression by PI3K/Akt pathway inhibitors. Chondrocytes were preincubated for 30 min with LY294002 or NL-71-101
and stimulated with OSM for 24 h. Impact on MMP-13 protein by representative Western blots is shown. Quantitative data represent the means±SE of 3 different
experiments.
317M. El Mabrouk et al. / Biochimica et Biophysica Acta 1773 (2007) 309–320Moreover, parthenolide did not affect OSM-induced c-Fos and
c-Jun activation (Fig. 6D).3.6. PI3K/Akt pathway inhibitors down-regulate
OSM-stimulated ADAMTS-4 and MMP-13 expression
Previously unknown role of PI3K/Akt pathway in
ADAMTS-4 and MMP-13 induction was also investigated.
PI3K inhibitor (LY294002) and Akt inhibitor (NL-71-101),
suppressed OSM-induced ADAMTS-4 mRNA and MMP-13
expression in human chondrocytes. The GAPDH RNA levels
were not affected by these treatments (Figs. 7 and 8). At higherFig. 9. Effect of JAK3 inhibition on OSM-stimulated Akt/PKB and ERK1/2 phospho
30 min and time-course effects of OSM on Akt phosphorylation and total Akt (A) a
The position of different proteins is indicated with arrows.concentration, NL-71-101 also abolished MMP-13 induction
(Fig. 8).
3.7. PI3K/Akt pathway is a downstream target of JAK/STAT
cascade
To investigate the possible cross talk between JAK/STAT
and Akt pathways, human chondrocytes were pretreated with
the JAK3 inhibitor, stimulated with OSM and protein extracts
analyzed at different time points. OSM stimulated Akt
phosphorylation within 5 min that declined by 30 min. JAK3
inhibitor down-regulated this phosphorylation without affecting
the total Akt levels. These results suggest that Akt isrylation. Quiescent human chondrocytes were pretreated with JAK3 inhibitor for
s well as on respective ERK1/2 (B) levels were measured by Western blotting.
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inhibitor affected other kinase activities, human chondrocytes
were pretreated with this inhibitor and phospho-ERK1/2 levels
were measured (Fig. 9B). JAK3-mediated Akt/PKB pathway
activation seemed to be specific since it did not affect OSM-
induced ERK1/2 phosphorylation.
4. Discussion
Aggrecanases and MMP-13 are the principal enzymes
responsible for sequential cleavage of cartilage aggrecan and
collagen respectively. Here we have shown that OSM
coordinately induces the expression of both enzymes in
human chondrocytes derived from femoral head of arthritic
patients. With the help of specific pharmacological and genetic
inhibitors we demonstrated that multiple pathways including
ERK, JAK/STAT and PI3K/Akt mediate OSM induction of
these proteases. There is cross talk between JAK/STAT and Akt
pathways. Interruption in OSM signaling could constitute an
important strategy for blocking its catabolic effects via
aggrecanases and MMP-13 in arthritis.
Other studies have investigated the impact of OSM in
combination with IL-1 on cartilage, however, these studies were
conducted on chondrocytes derived from either animal cartilage
or human knee cartilage or immortalized human chondrocyte
cell line [12,30,31]. To be physiologically and pathologically
relevant, it is important to study responses of human articular
chondrocytes from specific joints. It is more appropriate to
compare the effect of any cytokines in cells from the same
species and origins of joints. Indeed, certain molecular
differences between different human joints or chondrocyte
subgroups in response to IL-1 have been demonstrated [32,33].
We also found a high basal level of MMP-13 in some patients;
this is in agreement with the previously reported results [33],
which divided human chondrocytes in two subpopulations
based on the levels of MMP-13 expression.
Our results clearly and reproducibly show that OSM by itself
induces cartilage degradation, which was evaluated by GAG
release from aggrecan. This phenomenon could be attributed to
the induction of metalloproteinases such as ADAMTS-4 and
MMP-13. Contrary to our expectation from collagen degrada-
tion studies [34], the combination of OSM and IL-1β did not
have an additive effect on GAG release. It seems that maximal
induction capacity of cartilage can be attained by individual
treatments and cytokine combination would not further enhance
this capacity for GAG release. OSM-induced cartilage degrada-
tion seems to be mediated by ADAMTS-4 and MMP-13. In the
current study, the active forms of these enzymes are increased in
OSM-treated cartilage. Kashiwagi et al., [27] have demon-
strated that the full-length ADAMTS-4 of 70 kDa has little
activity against the Glu373–Ala374 site and has to be processed
to display stronger activity against this site.
The responsiveness of chondrocyte to OSM and IL-1β
regarding the induction of MMP-13 protein and ADAMTS-4
mRNA expression is preserved in primary cultures. OSM alone
is able to induce expression of these genes even at low
concentration. Our results are in disagreement with the currentview, which predominantly supports the inability of OSM alone
to induce MMPs and aggrecanases. This discrepancy could be
due to the cell source (bovine or human), and type of
chondrocyte (nasal, immortalized chondrocyte or knee
[12,30,31]), experimental conditions, stage of arthritis and
source of OSM (commercial versus home made) [30].
JAK/STAT pathway is intimately involved in the signaling
events initiated by OSM, activation of cell surface receptors
leading to MMPs and aggrecanases induction. JAK3 plays
crucial role for signaling by key immunoregulatory cytokines,
and selective JAK3 inhibitors are very effective in blocking
immune responses both in vitro and in vivo for transplant
rejection. Although, all JAK isoforms are expressed in human
chondrocytes and activated by OSM, only JAK3 seemed to
mediate MMP-13-induction by OSM since JAK2 inhibition had
no effect on this induction; which also has been demonstrated in
our previous study [22]. JAK2 or JAK3 inhibition attenuates
OSM induced ADAMTS-4 gene expression. The mechanisms
by which these two kinases regulate ADAMTS-4 expression
upon OSM stimulation in human chondrocytes remain to be
studied further. We demonstrated that OSM-induced MMP-13
via JAK2 independent mechanism. Song et al. [35] have shown
that OSM stimulates human adipose tissue-derived mesenchy-
mal stem cells proliferation through JAK3-dependent and
JAK2-independent mechanisms. Therefore, it seems likely
that each isoform has specific role.
STAT1 and STAT3 are activated upon OSM stimulation [22].
The activated JAKs are not specific for a particular STAT
substrate but the initial specificity for most STAT activation is
determined by specific interactions between STATs and the
respective receptors. Specific role of each STAT isoform in
chondrocytes is not known, however, STAT1 or STAT3 can
form a stable homodimer prior to activation [36]. STAT1 is
found in an activated state in the synovium of most but not all
RA patients [37]. Similarly, STAT3 is persistently activated in
Zymosan-induced models of arthritis [38]. Parthenolide has
been shown to block STAT3 phosphorylation on Tyr705
preventing its dimerization and translocation to nucleus [29].
Previously STAT1 was shown to be involved in the induction of
MMPs and TIMP-3 by OSM [22]. Current results demonstrate
that STAT3 binds to its consensus site containing oligonucleo-
tide, an activity inhibited by parthenolide. Inhibition of the
respective RNA/protein also suggests that STAT3 activity is
required for OSM-induction of ADAMTS-4 and MMP-13. In
an earlier study, combined OSM-IL-1 treatment did not result in
direct binding of STAT3 to MMP-1 promoter but STAT3
enhanced c-fos expression and AP-1 activity [39].
As a consequence of biological reductionism, intracellular
signaling pathways were previously considered as linear
cascades of MAPK, JAK/STAT and PI3 kinase pathways.
However, it seems likely that these signaling pathways are part
of cell specific networks with a complex cross talk. The
coordinate induction of ADAMTS-4 and MMP-13 by OSM
and their inhibition by U0126, JAK3 inhibitor, parthenolide,
LY294002 and NL-71-101 suggests that ERK1/2, JAK3-
STAT1/3, PI3K and Akt activation are needed for the
expression of these proteases. The cross talk of these kinases
319M. El Mabrouk et al. / Biochimica et Biophysica Acta 1773 (2007) 309–320does exist in human chondrocytes. We have previously shown
that OSM induces phosphorylation of ERK1/2 in both human
and bovine chondrocytes [22]. It has been demonstrated that
OSM activates ERK1/2 pathway via JAK1 [40]. Here we have
shown that JAK3 does not mediate OSM-induced ERK1/2
activation in human chondrocytes. In addition, JAK2 is not
implicated in activation of the target genes [22]. Therefore, the
requirement of JAKs for ERK1/2 activation by cytokines may
be cell type-specific. The cross talk of JAK/STAT with other
intracellular pathways is not limited to ERK1/2 pathway.
Interestingly, it has been demonstrated that activation of PI3K
pathway requires stimulation by JAKs. To gain further insight
into possible interaction of the JAK/STAT and PI3K/Akt
pathways, we attempted to find the sequence of these events.
Inhibition of Akt phosphorylation by the JAK3-specific
inhibitor suggests that Akt pathway is a downstream target of
JAK3 in chondrocytes. Time-dependent phosphorylation of
Akt in response to OSM suggests that this cytokine rapidly
activates PI3K/Akt pathway in human chondrocytes. This
observation was somewhat surprising as OSM has growth
inhibitory activity (the origin of term, oncostatin) while PI3K/
Akt pathway is generally associated with cell growth and
proliferation. Murine OSM (muOSM) increases synovial
fibroblast proliferation, pannus formation and invasion of
cartilage [5]. The intensity of such processes is augmented
when OSM and TNF-α combination is used in vivo [41]. These
effects of muOSM are mediated by induction of PI3K/Akt
pathway in mouse fibroblast cell lines [42]. Down-regulation of
both ADAMTS-4 and MMP-13 by the specific PI3K and Akt
inhibitors strongly supports the requirement of this pathway in
the induction of two proteases.
The observed stimulation of multiple pathways by OSM
including the growth and proliferation promoting ERK-
MAPK and PI3K/Akt pathways could explain diverse and
sometimes contradictory (pro-inflammatory versus anti-
inflammatory) properties of this cytokine [43]. Due to its
ability to induce TIMPs and to protect against LPS-induced
TNF-α production and lethality in vivo, OSM has been
regarded as an anti-inflammatory cytokine by some investi-
gators [43]. However, our current studies suggest a tissue-
damaging and pro-arthritic role for OSM. Attempts have been
made to block such actions with antibodies to OSM in RA-
like murine models of arthritis [6]. The signal transduction
pathways identified here could provide additional targets for
therapeutic interference. Agents such as parthenolide and
siRNAs may also block STAT3-dependent proliferation of
rheumatoid synovial fibroblasts.
5. Conclusion
We have shown for the first time that the expression of two
major cartilage-damaging proteases is coordinately induced by
OSM in human cartilage and chondrocytes, thereby supporting
its catabolic role. Inhibition of ERK1/2, JAK3/STAT1/STAT3
and PI3K/Akt pathways results in down regulation of
ADAMTS-4 and MMP-13 suggesting the pivotal role of these
signaling cascades and their cross talk in the up-regulation.These results also identify novel targets and their inhibitors that
could be potentially useful for diminishing OSM-driven
cartilage breakdown in arthritis. Inhibition of OSM and its
intracellular signaling molecules could increase the efficacy of
anti-IL-1 and TNF in combination therapy approaches.
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